HEALTHCAP VII ADVISOR AB

Investment decisions are made by the managing partners of HealthCap, who serve as advisors to the fund through HealthCap VII Advisor AB. The partnership is composed of medical doctors and PhDs who combine clinical and scientific backgrounds with decades of venture experience. Their expertise allows them to evaluate drug and device platforms at the molecular and clinical trial design level, which is central to the firm's reputation for high-conviction, board-intensive investments.

The firm sources heavily from the Karolinska Institute and connected Nordic academic research hospitals, where its partners have maintained decades-long relationships with scientists and clinician-researchers. This academic origination model gives HealthCap VII early visibility into preclinical work and first-in-human trial data before it reaches broader investor awareness. The firm's track record of spinning out Karolinska-sourced assets into publicly listed and acquired companies reinforces this proprietary pipeline.

HealthCap VII invests primarily in European-originated companies, often those seeking to enter the US market for FDA approval or strategic partnering. While the firm does not run a dedicated US office, many portfolio companies establish a US clinical or commercial presence post-investment. The firm's network of co-investors, including US crossover funds and large pharma venture arms, provides the bridge between European science and US market execution.

HealthCap VII Advisor AB is the legal advisory entity that provides investment management services exclusively to the HealthCap VII fund. It is separate from both the fund's limited partnership vehicle and earlier or later vintage HealthCap funds. Each HealthCap fund generation typically has a distinct advisor entity, reflecting the progression of the partnership and the specific regulatory and fiscal structure required for each vintage's investors.

The fund focuses on development-stage life science investing, typically entering at Series B or later when a company has generated human proof-of-concept data. HealthCap VII also participates in crossover rounds, supporting portfolio companies as they approach regulatory milestones and public listings. The firm avoids seed-stage discovery exposure, preferring to commit capital once therapeutic or device hypotheses are validated in clinical settings.